Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Alaunos Therapeutics, Inc.ZIOP · Entity 8339 | President | January 29, 2020 | January 31, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Alaunos Therapeutics, Inc.
Report date January 29, 2020 · Filed January 31, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 275,778 |
Reported balance
After 2020-01-29 transaction · row 1
1 source rowRow 1 · 2020-01-29 · Grant · Acquired 80,500 · Balance 275,778 F1: 26,834 shares shall vest on 12/31/2020 and 26,833 shares shall vest on each of 12/31/2021 and 12/31/2022. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.21 · Expires 2030-01-29 | Direct | 123,900 |
Reported balance
After 2020-01-29 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2020-01-29 · Grant · Acquired 123,900 · Balance 123,900 F2: 1/12th of the shares underlying this option will vest in equal quarterly installments commencing one quarterly period after 12/31/2019. |
Filing footnotes · ownership attribution and instrument terms
F1: 26,834 shares shall vest on 12/31/2020 and 26,833 shares shall vest on each of 12/31/2021 and 12/31/2022.
F2: 1/12th of the shares underlying this option will vest in equal quarterly installments commencing one quarterly period after 12/31/2019.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 29, 2020 Filed Jan 31, 2020 21:51 UTC | Alaunos Therapeutics, Inc. ZIOP · Entity 8339 | GrantEmployee Stock Option (right to buy) · Derivative | 123,900 | $0.00 Strike: $4.21 | $0.00 |
DisclosureSEC source: 0001209191-20-005787 · doc4.xml · derivative · entry 2 MAUNEY DAVID M MD · CIK 0001305832 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 123,900 Underlying: Common Stock · 123,900 shares Expires 2030-01-29 F2 · derivative.exercise_date: 1/12th of the shares underlying this option will vest in equal quarterly installments commencing one quarterly period after 12/31/2019. Read SEC document |
| January 29, 2020 Filed Jan 31, 2020 21:51 UTC | Alaunos Therapeutics, Inc. ZIOP · Entity 8339 | GrantCommon Stock | 80,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-005787 · doc4.xml · nonDerivative · entry 1 MAUNEY DAVID M MD · CIK 0001305832 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 275,778 F1 · shares: 26,834 shares shall vest on 12/31/2020 and 26,833 shares shall vest on each of 12/31/2021 and 12/31/2022. Read SEC document |
| January 02, 2020 Filed Jan 3, 2020 22:10 UTC | Alaunos Therapeutics, Inc. ZIOP · Entity 8339 | SaleCommon Stock | 22,394 | $4.55 | $101,892.70 |
DisclosureSEC source: 0001209191-20-001180 · doc4.xml · nonDerivative · entry 1 MAUNEY DAVID M MD · CIK 0001305832 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 195,278 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person to satisfy withholding tax obligations upon the vesting of restricted stock grants. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.46 to $4.67, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 06, 2019 Filed Jan 8, 2019 21:22 UTC | Alaunos Therapeutics, Inc. ZIOP · Entity 8339 | GrantEmployee Stock Option (right to buy) · Derivative | 250,733 | $0.00 Strike: $2.24 | $0.00 |
DisclosureSEC source: 0001209191-19-002774 · doc4.xml · derivative · entry 2 MAUNEY DAVID M MD · CIK 0001305832 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,733 Underlying: Common Stock · 250,733 shares Expires 2029-01-06 F2 · derivative.exercise_date: 1/12th of the shares underlying this option will vest in equal quarterly installments commencing one quarterly period after 12/31/2018. Read SEC document |
| January 06, 2019 Filed Jan 8, 2019 21:22 UTC | Alaunos Therapeutics, Inc. ZIOP · Entity 8339 | GrantCommon Stock | 159,010 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-002774 · doc4.xml · nonDerivative · entry 1 MAUNEY DAVID M MD · CIK 0001305832 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 217,672 F1 · shares: 53,004 shares shall vest on 12/31/2019 and 53,033 shares shall vest on each of 12/31/2020 and 12/31/2021. Read SEC document |
| November 08, 2017 Filed Nov 9, 2017 21:41 UTC | Alaunos Therapeutics, Inc. ZIOP · Entity 8339 | PurchaseCommon Stock | 4,270 | $4.68 | $19,983.60 |
DisclosureSEC source: 0001209191-17-059986 · doc4.xml · nonDerivative · entry 1 MAUNEY DAVID M MD · CIK 0001305832 · EVP and Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,662 Read SEC document |
| September 28, 2017 Filed Oct 2, 2017 20:31 UTC | Alaunos Therapeutics, Inc. ZIOP · Entity 8339 | GrantEmployee Stock Option (Right to Buy) · Derivative | 500,000 | $0.00 Strike: $6.19 | $0.00 |
DisclosureSEC source: 0001209191-17-054636 · doc4.xml · derivative · entry 1 MAUNEY DAVID M MD · CIK 0001305832 · EVP and Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 500,000 Underlying: Common Stock · 500,000 shares Expires 2027-09-28 F1 · derivative.exercise_date: 166,667 shares subject to the option shall vest on each of 9/28/2018 and 9/28/2019; 166,666 shares subject to the option shall vest on 9/28/2020. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.